bioMérieux S.A./€BIM
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About bioMérieux S.A.
bioMérieux S.A. is a French company specialized in the field of in vitro diagnostics, operating within the healthcare industry. The company develops, manufactures, and markets diagnostic solutions that are primarily used for detecting disease-causing microorganisms. These solutions include a broad range of products, such as diagnostic tests for infectious diseases, cancer, and cardiovascular diseases, as well as industrial microbiological controls. Founded in 1963 by Alain Mérieux, bioMérieux is headquartered in Marcy-l'Étoile, near Lyon, France. The company has a global presence, serving clients around the world through a network of subsidiaries and distributors. Its competitive strength lies in its extensive product portfolio and commitment to research and development, enabling it to address evolving medical and industrial testing needs.
- Ticker
- €BIM
- Sector
- Health
- Primary listing
- PAR
- Employees
- 14,894
- Headquarters
- Marcy-l'Étoile, France
- Website
- www.biomerieux.com
bioMérieux S.A. Metrics
BasicAdvanced
€11B
23.16
€3.90
0.57
€0.98
1.08%
Price and volume
Market cap
€11B
Beta
0.57
52-week high
€115.80
52-week low
€64.00
Average daily volume
179K
Dividend rate
€0.98
Financial strength
Current ratio
2.302
Quick ratio
1.437
Long term debt to equity
0.044
Total debt to equity
0.098
Interest coverage (TTM)
39.74%
Profitability
EBITDA (TTM)
1,074.9
Gross margin (TTM)
56.13%
Net profit margin (TTM)
11.59%
Operating margin (TTM)
19.68%
Effective tax rate (TTM)
23.88%
Revenue per employee (TTM)
€270,000
Management effectiveness
Return on assets (TTM)
8.88%
Return on equity (TTM)
11.22%
Valuation
Price to earnings (TTM)
23.164
Price to revenue (TTM)
2.664
Price to book
2.48
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
18.237
Free cash flow yield (TTM)
5.48%
Free cash flow per share (TTM)
4.954
Dividend yield (TTM)
1.08%
Forward dividend yield
1.08%
Growth
Revenue change (TTM)
-3.18%
Earnings per share change (TTM)
23.04%
3-year revenue growth (CAGR)
2.54%
10-year revenue growth (CAGR)
6.98%
3-year earnings per share growth (CAGR)
6.27%
10-year earnings per share growth (CAGR)
12.96%
3-year dividend per share growth (CAGR)
4.86%
10-year dividend per share growth (CAGR)
11.39%
What the Analysts think about bioMérieux S.A.
Analyst ratings (Buy, Hold, Sell) for bioMérieux S.A. stock.
Analyst projections of the future price of bioMérieux S.A. stock.
Bulls say / Bears say
Q2 organic sales growth rebounded to 5%, rising to 7% excluding BIOFIRE respiratory panels, while the company’s four strategic growth drivers expanded 8.5%. This suggests its broader portfolio can offset weakness in seasonal respiratory testing. (bioMérieux)
SPINCHIP’s first troponin test launched in Europe in September, extending bioMérieux into rapid point-of-care testing for suspected heart attacks. The platform gives the company a new product avenue beyond its established infectious-disease diagnostics. (bioMérieux)
Free cash flow rose 76% to €299 million in the first half and bioMérieux ended June with €236 million of net cash. That financial headroom supports investment in new products and strategic growth. (bioMérieux)
The company cut its 2027–28 annual organic sales growth target to 3%–6%, from an average 7% previously, and lowered its operating-profit ambition. This points to a less confident medium-term growth outlook. (MarketScreener)
First-half organic sales were almost flat at 0.2%, while CEBIT fell 4.9% organically and gross margin declined. The weak underlying performance leaves less room for execution setbacks or cost pressure. (bioMérieux)
Demand remains vulnerable to weak respiratory seasons and cautious hospital spending: Q1 sales fell 3.9% organically, instrument sales dropped 18%, and microbiology sales in China declined. Persistent softness in these areas could make growth uneven and weigh on new installations. (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
bioMérieux S.A. Financial Performance
Revenues and expenses
bioMérieux S.A. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing bioMérieux S.A.
AllUSDEURGBP
Fund name | Fund size | €BIM weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.47% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.47% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.47% |
iShares STOXX Europe 600 Health Care€EXV4 | €709M | 0.24% |
iShares MSCI Europe Health Care Sector€ESIH | €890M | 0.20% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.